Kimberlee Drapkin Buys Shares of LENZ
Kimberlee Drapkin acquired 22,100 shares of LENZ on June 15, 2026.
Key Points
- Kimberlee Drapkin acquired 22,100 shares of LENZ on June 15, 2026.
- LENZ shares traded at $6.77, with insider buying from multiple executives.
- Analysts from Citigroup and HC Wainwright maintained 'buy' ratings with targets up to $38.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, Kimberlee Drapkin purchased 22,100 shares of LENZ. This insider transaction, which was not part of a pre-arranged trading plan, adds to the buying activity seen within the company.
Insider Buying and Selling at LENZ Therapeutics, Inc.
Several insiders at LENZ, including Zachary Scheiner, Frederic Guerard, James McCollum, Shelley Thunen, Kimberlee Drapkin, and Jeffrey George, each bought 22,100 shares on June 15, 2026. These transactions were not planned under Rule 10b5-1, reflecting a coordinated buying effort among the company's executives.
Other Institutional Activity in LENZ
Versant Venture Management, LLC increased its stake in LENZ by 2,656,888 shares, now holding 5,313,776 shares valued at approximately $48.6 million. BlackRock, Inc. also increased its position by 284,817 shares, bringing its total to 1,976,823 shares worth about $18.1 million. Meanwhile, FMR LLC reduced its holdings by 104,934 shares, ending with 3,597,784 shares valued at $32.9 million.
Analysts Set New Price Targets
On May 13, 2026, Citigroup maintained its 'buy' rating for LENZ with a $20 price target. HC Wainwright & Co. also maintained a 'buy' rating on May 12, 2026, with a target of $38. Piper Sandler downgraded the stock to 'hold' with a $12 target on the same day. The consensus among analysts remains favorable, with a majority recommending 'buy' ratings and price targets varying widely.
Bottom Line
The buying activity by Kimberlee Drapkin and other LENZ insiders on June 15, 2026, suggests confidence in the company's prospects. Institutional investors are also adjusting their positions, with some increasing their stakes significantly. Analyst opinions remain largely positive, with several maintaining 'buy' ratings and setting diverse price targets. As always, it's important to remember that insider transactions and analyst ratings are just parts of the broader picture investors consider.
Get LENZ Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $LENZ, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.